Bright Minds Biosciences Inc. (NASDAQ: DRUG) is going for a consolidation of its common shares on a five-to-one basis, a plan approved by the company’s board of directors in June.
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) saw a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 680,900 shares, a growth of 15.9% from the May 15th total of 587,600 shares. Based on an average daily volume of 695,200 shares, the days-to-cover ratio […]
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) saw a significant increase in short interest in May. As of May 31st, there was short interest totalling 680,900 shares, an increase of 15.9% from the May 15th total of 587,600 shares. Approximately 4.8% of the company’s shares are short sold. Based on an average daily volume […]
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the recipient of a large drop in short interest in May. As of May 15th, there was short interest totalling 587,600 shares, a drop of 12.9% from the April 30th total of 675,000 shares. Based on an average daily trading volume, of 691,100 shares, the days-to-cover […]
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the target of a large increase in short interest in April. As of April 30th, there was short interest totalling 675,000 shares, an increase of 38.1% from the April 15th total of 488,600 shares. Approximately 4.7% of the shares of the stock are short sold. Based […]